Veeda集团重新命名为Veeda生命科学,将服务从非专利药物扩大到包括新型药物开发。 Veeda Group rebrands to Veeda Lifesciences, broadening services from generics to include novel drug development.

Veeda集团已重新命名为Veeda生命科学组织,标志着它从以非专利商品为重点的CRO转向更广泛的药物开发服务提供者。 Veeda Group has rebranded as Veeda Lifesciences, marking its shift from a generics-focused CRO to a broader drug development services provider. 该公司现在通过四个单位提供非专利药品和新药服务:临床试验、健康志愿者服务、生物药剂服务以及临床和非临床检测服务。 The company now offers services for generics and novel drugs through four units: Clinical Trials, Healthy Volunteer Services, Biopharma Services, and Preclinical & Non-Clinical Testing Services. Veeda在5个国家开展业务,目的是扩大其全球覆盖面,并计划将来提出公共分享问题。 Operating in 5 countries, Veeda aims to expand its global reach and plans to propose a public share issue in the future.